RE:RE:RE:RE:RE:EY sees bolt-ons in the single to double digit billions now "Furthermore, Immunomedics was acquired for US$21 Billion and doesn't have the Platform Technology that ONCY's pelareorep can provide." -Noteable, just below.
-This is the important statement in the context of current valuation. I am not knowledgeable enough to know what Immunomedics had as its future expected outcomes at the time it was aquired. But big pharma did pay a lot of money for it.
If we are offering something even only partially as relevant and valuable as Immunomedics, I am cautiously encouraged.
I am also waiting for volume before I become more optimistic.